Frequent reactivation of herpes simplex virus among HIV-1-infected patients treated with highly active antiretroviral therapy.
The effect of highly active antiretroviral therapy (HAART) on control of herpes simplex virus (HSV) in human immunodeficiency virus (HIV) type 1-infected subjects is not known. Among 28 HAART-treated and 49 untreated subjects with HIV-1 and HSV-2 infections, mucosal HSV shedding (median, 18% and 29% of days positive for HSV DNA, respectively; P=.08) and HSV DNA level (median, 56,250 and 50,000 copies/mL, respectively; P=.20) were similar. Treated subjects reported significantly fewer days with HSV lesions, compared with untreated subjects (2.8% vs. 11.3% of days, respectively; P=.001). Thus, mucosal HSV shedding and HSV-2 reactivation were still frequent among treated subjects, even though HAART was associated with fewer days with HSV lesions.
Posavad
Christine M
CM
Department of Laboratory Medicine, University of Washington, and Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA. posavad@u.washington.edu
Wald
Anna
A
Kuntz
Steven
S
Huang
Meei Li
ML
Selke
Stacy
S
Krantz
Elizabeth
E
Corey
Lawrence
L
D000328:Adult; D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D004279:DNA, Viral / Q000032:analysis; D005260:Female; D005835:Genitalia / Q000821:virology; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1; D015498:HIV-2; D006561:Herpes Simplex / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D018258:Herpesvirus 2, Human / Q000235:genetics / Q000302:isolation & purification*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009061:Mouth Mucosa / Q000821:virology; D009092:Mucous Membrane / Q000821:virology; D018139:Simplexvirus / Q000235:genetics / Q000302:isolation & purification*; D017201:Virus Shedding
D044966:Anti-Retroviral Agents; D004279:DNA, Viral